On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and ...
Guidance for 2026 revenue was made explicit at $10 million, with commercialization now targeted for late 2026. The previous quarter did not provide specific 2026 revenue guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results